FDA accepts Par's ondansetron NDA

FDA accepted for review an NDA from Par Pharmaceutical Cos. Inc. (NYSE:PRX) for an ondansetron orally dissolving film strip to prevent nausea and vomiting associated with chemotherapy, radiotherapy an...